Are Upatinib extended-release tablets a biological agent?

Upadacitinib (Upadacitinib) sustained-release tablets, as a new type of small molecule oral drug, do not belong to the category of biological agents, but are selective Januskinase1 (JAK1) inhibitors. By precisely inhibiting the activity of JAK1, the drug effectively regulates the JAK-STAT signaling pathway, thereby reducing the levels of a variety of pro-inflammatory cytokines, achieving the purpose of reducing inflammatory reactions and relieving related symptoms.

Upadatinib exhibits unique advantages compared with biological agents. Biological agents are mostly protein drugs extracted or synthesized from living cells through biotechnology, such as monoclonal antibodies and recombinant proteins. They target specific targets and are highly specific and selective. However, the preparation process of these complex protein molecules is cumbersome and often requires injection, which is not only costly but may also bring certain risks of side effects.

On the contrary, as a small molecule drug, upadatinib has a simple structure and small molecular weight, which makes it easy to be absorbed orally, thereby improving bioavailability and convenience of medication. The drug can easily enter cells and interact directly with the target to achieve pharmacological effects. In addition, upadatinib is more economical in drug development and production, and its oral administration method also greatly improves patient compliance.

Upadatinib has been widely used in the treatment of a variety of immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, moderate to severe atopic dermatitis, and ankylosing spondylitis. Its oral administration method is convenient, and the drug quickly exerts its effect in the body, bringing significant symptom relief and improvement in quality of life to patients.

Although upadatinib overlaps with biological agents in their anti-inflammatory effects, there are significant differences in their drug structure, mechanism of action, and mode of administration. Therefore, upadatinib extended-release tablets should be regarded as a unique and effective small molecule drug that provides new treatment pathways and options for many patients.